NKT cell-dependent glycolipid–peptide vaccines with potent anti-tumour activity
作者:Regan J. Anderson、Benjamin J. Compton、Ching-wen Tang、Astrid Authier-Hall、Colin M. Hayman、Gene W. Swinerd、Renata Kowalczyk、Paul Harris、Margaret A. Brimble、David S. Larsen、Olivier Gasser、Robert Weinkove、Ian F. Hermans、Gavin F. Painter
DOI:10.1039/c4sc03599b
日期:——
Glycolipid–peptide conjugates designed to release vaccine components within target cells ensuring potent CD1d dependent T cell responses.
This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.
This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.
The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.